DGAP-News: SYGNIS Pharma AG: GBC Research values SYGNIS at

DGAP-News: SYGNIS Pharma AG / Key word(s): Research Update SYGNIS Pharma AG: GBC Research values SYGNIS at EUR42.6 million and issues a 'BUY' recommendation 17.07.2013 / 10:00 --------------------------------------------------------------------- Press Release GBC Research values SYGNIS at EUR42.6 million and issues a 'BUY' recommendation - This valuation amply exceeds the current market quotation and ascribes the shares a potential upside of nearly 70%. - This is the second analyst coverage done this year that evaluates the company much higher than the current market price, confirming the potential market upside of the shares. - GBC and Edison valuation support the robustness of the new business of SYGNIS. - GBC bases their analysis on the current portfolio, including QualiPhi(R), which was licensed to Qiagen and will be launched in the third quarter this year. Madrid/Heidelberg, 17 July 2013 - GBC Research, a German independent research house focusing on listed small, and midcap companies, has published a full analysis of the DNA amplification and sequencing company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange). As a result of GBC's analysis of the Company, the objective value of SYGNIS, taking into account the launch of QualiPhi(R) in the third quarter of 2013 - licensed by Qiagen - as well as the license of three further products this year: PrimPol, QualiPhi mutants and Double Switch, would reach EUR42.6 million. SYGNIS shares were listed at EUR2.75 on the Frankfurt stock exchange at close of markets on Friday, 12th July, 2013 and a market cap of about EUR26 million. The GBC analysis values the Company at a premium of nearly 70% to the close price last Friday. The out-licensing agreement with Qiagen for QualiPhi(R) in the DNA amplification space serves as a blueprint for other SYGNIS products. Since their development has already been completed, the entire product portfolio could be out-licensed in the current financial year. Based on this assumption, GBC expects first market sales for QualiPhi(R) to be generated in the current financial year. For 2014 GBC assumes a significant revenue increase, which should allow the company to achieve operational break-even. In future, SYGNIS expects to deliver additional product developments in the life sciences sector, which should lead to an acceleration of top-line growth. Different studies project high growth rates for next generation sequencing (NGS) technologies in the coming years, which are expected to average 22.7% compound annual growth rate (CAGR) through 2016. Following GBC's analysis, SYGNIS' broad product range places the Company in a very good position to benefit from this strong market growth, especially as the technologies developed by the Company have the potential to become new world standards in the area of DNA amplification and sequencing. 'For SYGNIS, to have two independent first level analysts, from two different institutions and countries, predicting a target valuation around EUR40 million, is a clear evidence of the strength of the new business approach and the important potential upside the share offers to investors' commented Pilar de la Huerta, CEO/CFO of SYGNIS. About SYGNIS Pharma AG: www.sygnis.de After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi(R) and is currently developing other products in the field of Next Generation Sequencing. For further information please contact: SYGNIS Pharma AG Pilar de la Huerta CEO/CFO Tel: +34-918063089 Email: pdelahuerta@sygnis.es # # # Disclaimer: Some statements included in this press release, relating neither to proven financial results nor to other historical data, should be viewed as forward-looking, i.e. not definitive. Such statements are mainly predictions of future results, trends, plans or goals. They should not be considered to be total guarantees since given their very nature, they are subject to known and unknown risks, as well as to aspects beyond human control, and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise said statements in light of new information or future results or for any other reason. # # # End of Corporate News --------------------------------------------------------------------- 17.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: SYGNIS Pharma AG Im Neuenheimer Feld 515 69120 Heidelberg Germany Phone: 06221 454-6 Fax: 06221 454-700 E-mail: contact@sygnis.de Internet: www.sygnis.de ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 221552 17.07.2013